Allogene Therapeutics, Inc. (ALLO) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$38.8M

EPS$-0.17

Market Cap$486.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Chang

CEO & Executive Director

Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.

Founded: 2017
Employees: 1
Headquarters: SOUTH SAN FRANCISCO, CA, United States
Website: allogene.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-13.27%

ROA?

-9.33%

D/E Ratio?

0.42

📊

Profitability Ratios

Current Ratio?

7.93

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jun 5, 2026 (in 10 days)

Annual Report (10-K) — Based on filing pattern

Jun 5, 2026

Predicted10-K

Mar 12, 2026

10-KQ4 202571d after period end

Mar 12, 2026

10-KFY 202571d after period end

Nov 6, 2025

10-QQ3 202537d after period end

Aug 13, 2025

10-QQ2 202544d after period end

May 13, 2025

10-QQ1 202543d after period end

Mar 13, 2025

10-KFY 202572d after period end

Mar 14, 2024

10-KFY 202474d after period end

Feb 28, 2023

10-KFY 202259d after period end

Loading company sections...

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

The morning brief, before the bell.

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades